Sökning: (L773:0732 183X OR L773:1527 7755) lar1:(liu) >
Randomized phase II...
-
Barlesi, FabriceHop Marseille, AP HP, Marseille, France
(författare)
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer : AVAPERL (MO22089).
- Artikel/kapitelEngelska2013
Förlag, utgivningsår, omfång ...
-
Alexandria, VA, USA :American Society of Clinical Oncology,2013
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-105275
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-105275URI
-
https://doi.org/10.1200/JCO.2012.42.3749DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
PURPOSE: Maintenance therapy is associated with improved survival in patients with non-small-cell lung cancer (NSCLC), but few studies have compared active agents in this setting. AVAPERL evaluated the safety and efficacy of bevacizumab with or without pemetrexed as continuation maintenance treatment.PATIENTS AND METHODS: Patients with advanced nonsquamous NSCLC received first-line bevacizumab 7.5 mg/kg, cisplatin 75 mg/m(2), and pemetrexed 500 mg/m(2) once every 3 weeks for four cycles. Those achieving response or stable disease were randomly assigned at a ratio of 1:1 to maintenance bevacizumab 7.5 mg/kg or bevacizumab 7.5 mg/kg plus pemetrexed 500 mg/m(2) once every 3 weeks until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS) after random assignment.RESULTS: In total, 376 patients received induction treatment, 71.9% achieved disease control, and 67.3% were randomly assigned to maintenance therapy, with 125 and 128 receiving single-agent bevacizumab and bevacizumab plus pemetrexed treatment, respectively. At a median follow-up of 8.1 months, PFS from random assignment was significantly improved in the bevacizumab plus pemetrexed arm (median, 3.7 v 7.4 months; hazard ratio, 0.48; 95% CI, 0.35 to 0.66; P < .001) per a stratified model. The PFS benefit extended across age, performance status, smoking history, and induction response (stable disease v partial response) subgroups. Any grade, grade ≥ 3, and serious adverse events occurred more often with bevacizumab plus pemetrexed maintenance. No new safety signals were observed.CONCLUSION: In an unselected population of patients with nonsquamous NSCLC who had achieved disease control with platinum-based chemotherapy plus bevacizumab, bevacizumab plus pemetrexed maintenance was associated with a significant PFS benefit compared with bevacizumab alone. The combination was well tolerated.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Scherpereel, ArnaudUniv Lille, Ctr Hosp Reg, Hop A Calmette, Lille, France
(författare)
-
Rittmeyer, AchimLungenfachklin Immenhausen, Immenhausen, Germany
(författare)
-
Pazzola, AntonioOsped Civile Santissima, Sassari, Italy
(författare)
-
Ferrer Tur, NeusHosp Son Llatzer, Palma De Mallorca, Spain
(författare)
-
Kim, Joo-HangYonsei Univ, Coll Med, Seoul 120749, South Korea
(författare)
-
Ahn, Myung-JuSungkyunkwan Univ, Sch Med, Seoul, South Korea
(författare)
-
Aerts, Joachim G J VAmphia Hosp, Breda, Netherlands
(författare)
-
Gorbunova, VeraNN Blokhin Canc Res Ctr Russia, Moscow, Russia
(författare)
-
Vikström, AndersÖstergötlands Läns Landsting,Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet,Lungmedicinska kliniken US(Swepub:liu)andvi77
(författare)
-
Wong, Elaine KF Hoffmann Roche, Basel, Switzerland
(författare)
-
Perez-Moreno, PabloF Hoffmann Roche, Basel, Switzerland
(författare)
-
Mitchell, LadaF Hoffmann Roche, Basel, Switzerland
(författare)
-
Groen, Harry J MUniv Med Ctr Groningen, Groningen, Netherlands
(författare)
-
Hop Marseille, AP HP, Marseille, FranceUniv Lille, Ctr Hosp Reg, Hop A Calmette, Lille, France
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of Clinical OncologyAlexandria, VA, USA : American Society of Clinical Oncology31:24, s. 3004-30110732-183X1527-7755
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Barlesi, Fabrice
-
Scherpereel, Arn ...
-
Rittmeyer, Achim
-
Pazzola, Antonio
-
Ferrer Tur, Neus
-
Kim, Joo-Hang
-
visa fler...
-
Ahn, Myung-Ju
-
Aerts, Joachim G ...
-
Gorbunova, Vera
-
Vikström, Anders
-
Wong, Elaine K
-
Perez-Moreno, Pa ...
-
Mitchell, Lada
-
Groen, Harry J M
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal of Clini ...
- Av lärosätet
-
Linköpings universitet